Stock listing
NASDAQ:LTGO Latigo Biotherapeutics, Inc. Stock
Home listing (NASDAQ) of Latigo Biotherapeutics, Inc.
Follow Latigo Biotherapeutics, Inc. into a list and get an email when it puts out news.
Share price · NASDAQ:LTGO
$13.00 USD -0.31 (-2.3%)
Close on Nov 20, 2026
- Day range
- $11.91 – $13.35 USDNov 20, 2026
- Volume
- 267,166 sharesNov 20, 2026
- Market cap
- $861.9M USDAt the close on Nov 20, 2026 · price × 66.30M shares outstanding
- Traded on an average day
- $5.42M USDMedian day 234,100 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026
Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NASDAQ:LTGO · Home | $13.00 USD | -0.31 (-2.3%) | 267,166 | $13.22 | $13.35 | $11.91 | $13.31 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:LTGO · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $13.00 | -0.31 | -2.3% | $13.22 | $13.35 | $11.91 | 267,166 | |
| $13.31 | -0.45 | -3.3% | $14.00 | $14.23 | $13.21 | 209,071 | |
| $13.76 | +1.16 | +9.2% | $12.56 | $14.11 | $12.56 | 661,609 | |
| $12.60 | -0.51 | -3.9% | $12.99 | $13.27 | $12.32 | 505,045 | |
| $13.11 | +0.18 | +1.4% | $12.99 | $13.22 | $11.75 | 406,524 | |
| $12.93 | -0.59 | -4.4% | $13.35 | $13.59 | $12.20 | 167,664 | |
| $13.52 | +0.19 | +1.4% | $13.36 | $14.35 | $13.36 | 198,821 | |
| $13.33 | -0.02 | -0.1% | $13.23 | $14.00 | $12.96 | 780,387 | |
| $13.35 | +0.75 | +6.0% | $12.59 | $13.90 | $12.59 | 326,381 | |
| $12.60 | -0.41 | -3.2% | $13.18 | $15.95 | $12.11 | 555,445 | |
| $13.01 | -1.03 | -7.3% | $13.21 | $13.29 | $10.45 | 424,277 | |
| $14.04 | -0.53 | -3.6% | $14.87 | $15.00 | $13.96 | 155,949 | |
| $14.57 | +1.06 | +7.8% | $13.53 | $15.10 | $13.53 | 244,858 | |
| $13.51 | -0.44 | -3.2% | $15.02 | $15.02 | $13.29 | 289,064 | |
| $13.95 | -1.59 | -10.2% | $15.65 | $15.70 | $13.66 | 216,168 | |
| $15.54 | -0.29 | -1.8% | $16.00 | $16.74 | $15.44 | 141,658 | |
| $15.83 | +0.62 | +4.1% | $15.27 | $16.06 | $15.14 | 187,418 | |
| $15.21 | -0.05 | -0.3% | $15.33 | $15.86 | $15.01 | 164,098 | |
| $15.26 | +0.24 | +1.6% | $15.14 | $15.49 | $14.24 | 165,322 | |
| $15.02 | -1.55 | -9.4% | $16.51 | $16.55 | $14.84 | 146,000 | |
| $16.57 | +0.23 | +1.4% | $16.36 | $17.67 | $16.19 | 119,400 | |
| $16.34 | +1.09 | +7.1% | $15.45 | $16.78 | $15.18 | 173,800 | |
| $15.25 | +0.95 | +6.6% | $14.37 | $15.56 | $14.25 | 147,800 | |
| $14.30 | +0.30 | +2.1% | $14.04 | $14.52 | $13.54 | 283,800 | |
| $14.00 | -0.76 | -5.1% | $14.96 | $15.11 | $13.85 | 207,400 | |
| $14.76 | +0.76 | +5.4% | $14.09 | $14.90 | $13.50 | 242,900 | |
| $14.00 | -1.71 | -10.9% | $15.74 | $15.74 | $13.85 | 220,600 | |
| $15.71 | -0.31 | -1.9% | $16.12 | $16.51 | $15.56 | 346,800 | |
| $16.02 | +0.02 | +0.1% | $16.00 | $16.56 | $15.80 | 133,000 | |
| $16.00 | +1.21 | +8.2% | $14.84 | $16.08 | $14.61 | 184,200 | |
| $14.79 | -0.73 | -4.7% | $15.52 | $15.52 | $14.60 | 265,100 | |
| $15.52 | -0.74 | -4.6% | $16.22 | $16.35 | $15.27 | 241,500 | |
| $16.26 | -0.37 | -2.2% | $16.77 | $16.89 | $16.06 | 544,500 | |
| $16.63 | +0.73 | +4.6% | $16.06 | $17.07 | $15.87 | 590,000 | |
| $15.90 | -0.79 | -4.7% | $16.80 | $16.90 | $15.67 | 276,600 | |
| $16.69 | -0.01 | -0.1% | $16.70 | $17.55 | $16.48 | 436,700 | |
| $16.70 | -1.40 | -7.7% | $18.04 | $18.32 | $16.25 | 532,600 | |
| $18.10 | +0.62 | +3.5% | $17.33 | $18.50 | $17.30 | 955,200 | |
| $17.48 | +0.33 | +1.9% | $17.15 | $17.84 | $16.19 | 260,300 | |
| $17.15 | -0.61 | -3.4% | $17.81 | $18.26 | $17.00 | 275,700 | |
| $17.76 | -2.21 | -11.1% | $19.73 | $20.54 | $17.67 | 340,700 | |
| $19.97 | -0.85 | -4.1% | $20.77 | $20.79 | $19.71 | 214,600 | |
| $20.82 | -0.29 | -1.4% | $21.11 | $21.33 | $20.01 | 418,800 | |
| $21.11 | -1.44 | -6.4% | $22.80 | $23.11 | $21.00 | 411,400 | |
| $22.55 | -1.38 | -5.8% | $24.18 | $24.80 | $22.21 | 1,488,200 | |
| $23.93 | +0.87 | +3.8% | $23.14 | $24.80 | $23.09 | 431,000 | |
| $23.06 | +0.05 | +0.2% | $23.00 | $24.33 | $22.75 | 438,900 | |
| $23.01 | +0.37 | +1.6% | $22.50 | $24.75 | $22.48 | 221,400 | |
| $22.64 | +0.49 | +2.2% | $22.33 | $23.79 | $22.33 | 164,800 | |
| $22.15 | +0.61 | +2.8% | $21.76 | $23.22 | $21.50 | 178,700 | |
| $21.54 | -1.26 | -5.5% | $22.78 | $23.17 | $21.28 | 177,200 | |
| $22.80 | -0.93 | -3.9% | $23.72 | $23.98 | $22.44 | 190,400 | |
| $23.73 | +0.69 | +3.0% | $23.25 | $24.40 | $22.21 | 326,800 | |
| $23.04 | +0.56 | +2.5% | $22.68 | $23.57 | $22.02 | 226,400 | |
| $22.48 | +0.71 | +3.3% | $21.99 | $23.41 | $21.82 | 229,300 | |
| $21.77 | -0.49 | -2.2% | $22.58 | $23.85 | $21.40 | 163,200 | |
| $22.26 | +0.24 | +1.1% | $22.50 | $23.77 | $21.26 | 286,600 | |
| $22.02 | -2.21 | -9.1% | $24.41 | $24.70 | $21.75 | 155,000 | |
| $24.23 | -0.77 | -3.1% | $25.21 | $25.81 | $24.23 | 217,700 | |
| $25.00 | +0.87 | +3.6% | $24.15 | $25.93 | $24.08 | 235,500 | |
| $24.13 | +1.56 | +6.9% | $22.64 | $24.79 | $22.37 | 137,900 | |
| $22.57 | +0.57 | +2.6% | $22.07 | $22.76 | $21.74 | 142,800 | |
| $22.00 | -0.37 | -1.7% | $22.62 | $25.00 | $21.42 | 234,100 | |
| $22.37 | +0.97 | +4.5% | $21.52 | $22.90 | $20.64 | 197,200 | |
| $21.40 | +0.46 | +2.2% | $20.75 | $21.71 | $20.52 | 82,700 |
- Ticker
- NASDAQ:LTGO
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- NASDAQ
- Currency
- USD
What changed lately
Latest news release · Nov 5, 2026
Latigo Biotherapeutics Reports Third Quarter 2026 Financial Results and Recent Business Highlights
Latest deck · September 2026
Investor Presentation (September 2026)
Investor deck · 42 slides
Latest news
Latigo Biotherapeutics Reports Third Quarter 2026 Financial Results and Recent Business Highlights
Nov 5, 2026
Closed $13.01 (-7.3%) on Nov 5, 2026
Latigo Biotherapeutics Announces CEO Transition to Support the Company’s Next Phase of Growth
Nov 5, 2026
Closed $13.01 (-7.3%) on Nov 5, 2026
Latigo Biotherapeutics to Participate in Upcoming Investor Conferences in November
Nov 3, 2026
Closed $14.04 (-3.6%) on Nov 4, 2026
LTGO: Onzotrigine delivers rapid, superior pain relief with strong opioid-sparing potential in late-stage trials
Sep 3, 2026
Closed $23.04 (+2.5%) on Sep 4, 2026
Latigo Biotherapeutics Price Target Announced at $36.00/Share by Leerink Partners
Sep 1, 2026
Closed $22.26 (+1.1%) on Sep 1, 2026
Latigo Biotherapeutics Ups IPO to 19.2 Million Shares
Aug 7, 2026
Closed $18.25 (+1.4%) on Aug 7, 2026
Latigo Biotherapeutics, Inc. on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 6 in the last 12 months · 6 in all · newest Nov 5, 2026 · oldest 2026
- Decks
- 1 deck · latest September 2026
Where Latigo Biotherapeutics, Inc. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NASDAQ:LTGO · Home listing · This page | NASDAQ | United States | USD |
| BOATS:LTGO | BOATS | United States | USD |
Valuation
Price/book 2.2× against a median of 2.5×: 6th lowest of 11 Biotechnology companies shown. Statements: Year to Dec 31, 2025 · balance Sep 30, 2026 · price Nov 20, 2026
- Enterprise value
- $460.7M USD
- P/E
- Loss
- EV/sales
- No revenue
- EV/EBITDA
- Negative EBITDA
- Price/book
- 2.2×
- Gross margin
- No revenue
- Operating margin
- No revenue
- Net margin
- No revenue
- Debt to equity
- 0.0×
- Beta vs S&P 500
- Under 6 months of closes
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Latigo Biotherapeutics, Inc. · NASDAQ:LTGO | US$861.9M | US$460.7M | n/a | n/a | n/a | 2.2× | n/a | 0.0× | n/a |
| Metis TechBio Co., Ltd. Class H · HKEX:7666 | US$918.1M | US$487.6M | n/a | 223× | n/a | 2.0× | −373.2% | 0.0× | n/a |
| InventisBio, Co., Ltd. Class A · SSE:688382 | US$897.5M | US$712.7M | n/a | 67.0× | n/a | 4.6× | −533.7% | 0.0× | n/a |
| InnoCare Pharma Ltd. Class A · SSE:688428 | US$894.7M | −US$209.0M | 9.3× | −0.6× | −2.3× | 0.8× | 27.1% | 0.1× | n/a |
| Immatics N.V. · NASDAQ:IMTX | US$878.3M | US$375.4M | n/a | 7.9× | n/a | 1.8× | −534.1% | 0.0× | 1.40 |
| Bio-Thera Solutions, Ltd. Class A · SSE:688177 | US$878.1M | US$924.2M | n/a | 5.9× | n/a | 137× | −42.0% | 14.3× | n/a |
| Suzhou Ribo Life Science Co. Ltd. Class H · HKEX:6938 | US$875.5M | US$580.6M | n/a | 26.1× | n/a | 3.4× | −187.2% | 0.2× | n/a |
| Aktis Oncology, Inc. · NASDAQ:AKTS | US$868.0M | US$385.9M | n/a | 31.2× | n/a | 1.9× | −706.8% | 0.0× | 1.21 |
| Pharming Group NV · EURONEXT:PHARM | US$840.1M | US$766.3M | 34.4× | 2.0× | 19.8× | 2.9× | 6.3% | 0.4× | n/a |
| Corvus Pharmaceuticals, Inc. · NASDAQ:CRVS | US$815.7M | US$613.4M | n/a | n/a | n/a | 3.9× | n/a | 0.0× | 1.64 |
| Odyssey Therapeutics, Inc. · NASDAQ:ODTX | US$815.2M | US$512.7M | n/a | n/a | n/a | 2.2× | n/a | 0.1× | 1.11 |
| Median of the others | US$876.8M | US$546.7M | 21.9× | 17.0× | 8.7× | 2.5× | −280.2% | 0.1× | 1.31 |
Forecasts
4 strong buy · Analysts' consensus from EODHD, read Nov 18, 2026. Not 6ix's view and not investment advice.
- Price target
- 52.25 USD · Analysts' mean
- EPS, year to Dec 2026
- -2.71 · 3 analysts
Team and board
Officers
| Officer | Role |
|---|---|
| Todd Smith | president and chief executive officer, Director |
| Neha Krishnamohan | Chief Financial Officer and Chief Business Officer |
| Ada Kumar | Vice President, Medical Affairs |
| Anil Chhettry | Vice President, Chemistry, Manufacturing and Controls |
| Becky Baggett | Vice President, Clinical Operations |
| Ben Vaughn | Vice President, Biostatistics |
| Bryan Moyer | Senior Vice President, Discovery |
| Caroline Dougherty | Vice President, Corporate Development |
| Cynthia Voong | Vice President, Clinical Operations |
| Holly Carlisle | Vice President, Translational Science |
| Julia Chapman | Senior Vice President, Operations |
| Mike Kaufman | Vice President, Chemistry |
| Naomi Lowy | Senior Vice President, Global Regulatory Affairs |
| Polina German | Senior Vice President, Clinical Pharmacology and Translational |
| Sabrina Nieder | Vice President, Corporate Controller |
| Tim Clark | Vice President, Government Affairs |
| Beth Seidenberg | Founding Managing Director, Westlake BioPartners |
| Kevin Raidy | Senior Managing Director, Blue Owl Capital |
| Neil Singla | Chief Medical Officer |
Board
| Director | Role |
|---|---|
| Timothy P. Walbert | Chair, Board of Directors |
| Jim Tananbaum | Director |
| Sara Bonstein | Independent Director |
| Todd Smith | president and chief executive officer, Director |
Events
| Quarter | Results | Share move |
|---|---|---|
| Q3 2026 | Nov 5, 2026 · Before open | −7.3% |
| Q2 2026 | Sep 3, 2026 · After close | +2.5% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Investor Presentation (September 2026) | Investor deck | 42 slides | September 2026 |
IPO
Priced at US$18.00 a share on Aug 6, 2026.
- Price
- US$18.00 a share
- Shares offered
- 19,200,000 shares of common stock
- Offering size
- US$345.6 million
- Underwriters' option
- Up to 2,880,000 more shares
- Listing
- LTGO on the Nasdaq Global Select Market
- Underwriters
- Goldman Sachs & Co. LLC, Jefferies, Leerink Partners, Guggenheim Securities · In the order on the cover
Steps
| Step | When |
|---|---|
| Draft sent to the SEC in confidence | Mar 27, 2026 |
| Filed publicly | Jul 17, 2026 |
| Amended twice | Newest Aug 4, 2026 |
| Shares registered with an exchange | Aug 4, 2026 |
| Declared effective by the SEC | Aug 6, 2026 |
| Final prospectus, with the price | Aug 7, 2026 |
Filings
| Filing | Filed |
|---|---|
| 424B4 · Prospectus | Aug 7, 2026 |
| EFFECT · Notice that a registration is effective | Aug 6, 2026 |
| S-1MEF · Registration of more shares for the same offering | Aug 6, 2026 |
| CERT · Exchange's certificate of listing | Aug 6, 2026 |
| 8-A12B · Registration of shares for listing on an exchange | Aug 4, 2026 |
| S-1/A · Registration statement, amended | Aug 4, 2026 |
| S-1/A · Registration statement, amended | Aug 3, 2026 |
| S-1 · Registration statement | Jul 17, 2026 |
| DRS/A · Draft registration statement, amended | Jun 5, 2026 |
| DRS/A · Draft registration statement, amended | May 18, 2026 |
All 11 filings
| Filing | Filed |
|---|---|
| DRS · Draft registration statement | Mar 27, 2026 |
Open IPO · From the cover of the final prospectus (424B4) filed Aug 7, 2026
Financials
Annual, in USD
Income statement
| Line | FY2025 | FY2024 |
|---|---|---|
| Revenue | 0 | 0 |
| Research and development | 99.5M | 56.8M |
| Selling, general and administrative | 10.9M | 6.67M |
| Operating income | -110.4M | -63.5M |
| Depreciation and amortization | 249.0K | 244.0K |
| EBITDA | -110.1M | -63.2M |
| Income before tax | -109.2M | -61.2M |
| Net income | -109.2M | -61.2M |
| Earnings per share, basic | -1.81 | -1.02 |
Balance sheet
| Line | FY2025 | FY2024 |
|---|---|---|
| Cash and equivalents | 69.4M | 17.9M |
| Current assets | 73.8M | 21.2M |
| Total assets | 75.5M | 22.9M |
| Accounts payable | 5.01M | 7.07M |
| Current liabilities | 18.4M | 14.4M |
| Total liabilities | 307.2M | 152.5M |
| Shareholders' equity | -231.7M | -129.6M |
| Shares outstanding | 60.2M | 60.2M |
Cash flow
| Line | FY2025 | FY2024 |
|---|---|---|
| Cash from operations | -97.6M | -51.0M |
| Capital spending | -136.0K | -72.0K |
| Free cash flow | -97.7M | -51.0M |
| Cash from financing | 149.5M | 607.0K |
| Change in cash | 51.8M | -50.4M |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 4 · Change in ownership | Nov 18, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Nov 18, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Nov 18, 2026 | Insider trade | SEC |
| SCHEDULE 13G · Big-stake notice | Nov 16, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Nov 13, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 6, 2026 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Nov 5, 2026 | Quarterly report | SEC |
| 8-K · Current report | Nov 5, 2026 | Results | SEC |
| SCHEDULE 13G · Big-stake notice | Oct 29, 2026 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Sep 3, 2026 | Quarterly report | SEC |
All 49 filings
Cap table
Built by 6ix from Latigo Biotherapeutics, Inc.’s releases · as of Sep 1, 2026
- Common shares
- 66,299,347
- Fully diluted
- 66,299,347
Fully diluted
| Line | Shares | As of |
|---|---|---|
| Common shares | 66,299,347 | Sep 1, 2026 |
Share count over time
| Count | Shares |
|---|---|
| Sep 1, 2026 | 66,299,347 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Beth C Seidenberg Other companies: Kyverna Therapeutics, Inc. (Director · Since at least Feb 7, 2024); Sagimet Biosciences Inc. - Series A (Director · Since at least Jul 13, 2023); Vera Therapeutics, Inc. (Director · Since at least May 13, 2021); Acelyrin, Inc. (Director · May 4, 2023 – May 21, 2025 · Past); Progyny, Inc. (Director · Oct 24, 2019 – May 23, 2024 · Past); Armo Biosciences Inc. (Director · Jan 25, 2018 – Jun 22, 2018 · Past); Atara Biotherapeutics, Inc. (Director · Oct 15, 2014 – May 31, 2023 · Past); Epizyme Inc (Director · May 30, 2013 – Jun 30, 2019 · Past); Tesaro Inc (Director · Jun 27, 2012 – Jan 22, 2019 · Past) | Director · Since at least Aug 6, 2026 |
| Beth Seidenberg Other companies: Sagimet Biosciences Inc. - Series A (Lead Independent Director · Since at least Nov 4, 2026); Vera Therapeutics, Inc. (Founding Managing Director, Westlake Village BioPartners · Since at least Nov 4, 2026); Kyverna Therapeutics, Inc. (Independent Director · Since at least May 29, 2026) | Founding Managing Director, Westlake BioPartners · Since at least Aug 10, 2026 |
| Sara Bonstein Other companies: Xilio Therapeutics, Inc. (Chair of the Board · Since at least Jun 15, 2022); Scpharmaceuticals Inc (Director · Since at least Jun 14, 2022); Insmed Incorporated (Chief Financial Officer · Since at least May 11, 2022) | Director · Since at least Aug 6, 2026 |
| Nima Farzan Other companies: Keros Therapeutics, Inc. (Director · Since at least May 30, 2024); Kinnate Biopharma Inc (CHIEF EXECUTIVE OFFICER, Director · Apr 3, 2024 – Apr 3, 2024 · Past) | President and CEO, Director · Since at least Aug 6, 2026 |
| Jim Tananbaum Other companies: Alumis Inc. (Director · Since at least Apr 1, 2026) | Director · Since at least Aug 10, 2026 |
| Ada Kumar | Vice President, Medical Affairs · Since at least Nov 4, 2026 |
| Anil Chhettry | Vice President, Chemistry, Manufacturing and Controls · Since at least Nov 4, 2026 |
| Becky Baggett | Vice President, Clinical Operations · Since at least Nov 4, 2026 |
| Ben Vaughn | Vice President, Biostatistics · Since at least Nov 4, 2026 |
| Bryan Moyer | Senior Vice President, Discovery · Since at least Nov 4, 2026 |
All 24 people
| Person | Seat |
|---|---|
| Caroline Dougherty | Vice President, Corporate Development · Since at least Nov 4, 2026 |
| Cynthia Voong | Vice President, Clinical Operations · Since at least Nov 4, 2026 |
| Holly Carlisle | Vice President, Translational Science · Since at least Nov 4, 2026 |
| Julia Chapman | Senior Vice President, Operations · Since at least Nov 4, 2026 |
| Kevin Raidy | Senior Managing Director, Blue Owl Capital · Since at least Nov 5, 2026 |
| Mike Kaufman | Vice President, Chemistry · Since at least Nov 4, 2026 |
| Naomi Lowy | Senior Vice President, Global Regulatory Affairs · Since at least Nov 4, 2026 |
| Neha Krishnamohan | Chief Financial Officer and Chief Business Officer · Since at least Nov 4, 2026 |
| Neil Singla | Chief Medical Officer · Since at least Aug 6, 2026 |
| Polina German | Senior Vice President, Clinical Pharmacology and Translational · Since at least Nov 4, 2026 |
| Sabrina Nieder | Vice President, Corporate Controller · Since at least Nov 4, 2026 |
| Tim Clark | Vice President, Government Affairs · Since at least Nov 4, 2026 |
| Timothy P. Walbert | Chair, Board of Directors · Since at least Nov 5, 2026 |
| Todd Smith | Director · Since at least Aug 6, 2026 |
Log in to ask 6ix AI your own questions about Latigo Biotherapeutics, Inc.